Scalable, single-use solutions for purification of viral vectors
Industrialization of cell and gene therapies requires robust, scalable manufacturing processes. Purification of viral vectors can be achieved using scalable, single-use technologies including direct-flow filtration (depth and sterile), membrane-based ion exchange chromatography, and tangential-flow filtration (TFF). Here we present a strategy for using these technologies from Pall for LV manufacturing platforms.
Speaker
Todd Sanderson
Sr. Manager R&D
Pall, USA
Todd has been with Pall since 2006. He has over 20 years of research experience with expertise in mammalian cell culture, process development and analytical method development. He currently leads the Gene Therapy Upstream Cell Culture and Analytics Team in the Biotech Process R&D group. He holds a B.S. in Biochemistry and B.S. in Psychology from Michigan State University. When not at work, Todd enjoys gardening and spending time with his young children.
Learn about Transient transfection at large scale for clinical AAV9 vector manufacturing
Watch Rachel Legmann’s video presented during ICST 2020 Virtual event.
Biotech | Pall Corporation webinar series
Meet the authors from the ‘Insights on Successful Gene Therapy Manufacturing and Commercialization’ ebook